不同剂量重组人生长激素治疗幼女中枢性性早熟的临床效果

Clinical effect of different doses of recombinant human growth hormone in the treatment of central precocious puberty in young girls

目的探究不同剂量重组人生长激素治疗幼女中枢性性早熟的临床效果。方法选取2018年1月至2019年11月于本院就诊的幼女中枢性性早熟患儿50例作为研究对象,随机分为对照组和观察组,各25例。对照组予以大剂量[0.5 IU/(kg·d)]重组人生长激素治疗,观察组予以小剂量[0.2 IU/(kg·d)]重组人生长激素治疗,比较两组临床效果。结果治疗前,两组子宫体积、卵巢体积比较差异无统计学意义;治疗后,观察组子宫体积、卵巢体积均明显优于对照组,差异有统计学意义(P<0.05)。治疗前,两组性激素水平、生长发育指标比较差异无统计学意义;治疗后,观察组性激素水平、生长发育指标均明显优于对照组,差异有统计学意义(P<0.05);两组治疗前后第二性征比较差异均无统计学意义。结论中枢性性早熟患儿予以小剂量重组人生长激素治疗,能显著改善患儿临床症状及性激素水平,控制病情进展,且不同剂量对第二性征无明显影响。

Objective To explore the clinical effects of different doses of recombinant human growth hormone in the treatment of central precocious puberty in young girls.Methods 50cases of young girls with central precocious puberty who were treated in our hospital from January 2018 to November 2019 were selected as the research objects,and they were randomly divided into a control group and an observation group,with 25 cases in each group.The control group was treated with high-dose[0.5 IU/(kg·d)]recombinant human growth hormone,and the observation group was treated with low-dose[0.2 IU/(kg·d)]recombinant human growth hormone to compare the clinical effects of the two groups.Results Before treatment,there was no statistically significant difference in uterine volume and ovarian volume between the two groups;after treatment,the uterine volume and ovarian volume in the observation group were significantly better than those in the control group,and the difference was statistically significant(P<0.05).Before treatment,there was no statistically significant difference in sex hormone levels and growth and development indexes between the two groups;after treatment,the sex hormone levels and growth and development indexes in the observation group were significantly better than those in the control group,and the difference was statistically significant(P<0.05);there was no statistically significant difference in the secondary sex characteristics before and after.Conclusion The treatment of low-dose recombinant human growth hormone in children with central precocious puberty can significantly improve the children's clinical symptoms and sex hormone levels,control the progression of the disease,and different doses have no significant effect on secondary sexual characteristics.